Clinical Neuropharmacology最新文献

{"title":"Meta-analysis of Indobufen Combined With Clopidogrel in the Treatment of Ischemic Stroke Patients.","authors":"Weiwei Yuan, Yan Shao","doi":"10.1097/WNF.0000000000000642","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000642","url":null,"abstract":"<p><strong>Objectives: </strong>Currently, there is a paucity of optimal treatment method for ischemic stroke. This study conducted a meta-analysis of the application value of indobufen combined with clopidogrel in the field of ischemic stroke.</p><p><strong>Methods: </strong>The randomized controlled trials of indobufen combined with/without clopidogrel for the treatment of ischemic stroke were retrieved in Cochrane Library, PubMed, and CNKI from the establishment time of database to November 28, 2023. Cochrane risk-of-bias tool and Review Manager software were used for study quality evaluation and meta-analysis, respectively.</p><p><strong>Results: </strong>A total of 5 studies were ultimately included, published from 2021 to 2023, with a total of 408 patients. The meta-analysis results showed that the intervention group had a higher effective rate in treating stroke than the control group, with statistically significant difference (94.25% vs 75.29%, relative risk = 1.25, 95% confidence interval [CI] [1.14, 1.37], P < 0.00001), and there was no significant heterogeneity among the studies (P = 0.64, I2 = 0%). In addition, the meta-analysis results indicated that indobufen combined with clopidogrel decreased National Institutes of Health Stroke Scale score (mean difference [MD] = -3.52, 95% CI [-5.7, -1.35], P = 0.001), fibrinogen (MD = -0.65, 95% CI [-1.1, -0.2], P = 0.004), platelet aggregation (MD = -5.84, 95% CI [-6.96, -4.73], P < 0.00001), whole blood low shear viscosity (MD = -4.38, 95% CI [-4.81, -3.94], P < 0.00001), and whole blood high shear viscosity (MD = -0.96, 95% CI [-1.19, -0.73], P < 0.00001) and elevated thrombin time (MD = 0.42, 95% CI [0.09, 0.74], P = 0.01), but had no statistical effects on activated partial thromboplastin time and adverse reactions.</p><p><strong>Conclusion: </strong>The dual antiplatelet therapy regimen using indobufen and clopidogrel is suitable for the treatment of ischemic stroke, which can effectively alleviate neurological damage and inhibit cerebral thrombogenesis.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Features and ICHD Headache Diagnoses for Patients With Prominent Craniofacial Pain Referred by a Rhinologist to Headache Specialists.","authors":"Ashhar Ali, Odei Alayyas, Jyotika Singh, Abdulmalik Saleem, John Craig","doi":"10.1097/WNF.0000000000000641","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000641","url":null,"abstract":"<p><strong>Objectives: </strong>Most patients diagnosed with \"sinus headache\" are misdiagnosed and mistreated. These patients are often referred to otolaryngology for sinus disease evaluation. However, collaborations between rhinologists and headache specialists for \"sinus headaches\" have not been investigated. This study aimed to report the clinical features and headache diagnoses of patients referred to headache specialists for prominent craniofacial pain.</p><p><strong>Methods: </strong>We conducted a retrospective study of patients presenting with craniofacial pain to rhinologists and subsequently referred to a headache specialist for presumed, nonsinogenic, craniofacial pain. Records from a total of 98 patients were reviewed, and information regarding demographics, gender, nasal endoscopy findings, SNOT-22 (Sino-Nasal Outcome Test-22 questionnaire) score, ICHD (International Classification of Headache Disorders) headache diagnosis, and headache characteristics were extracted.</p><p><strong>Results: </strong>Nasal endoscopies performed by the rhinologists were normal in 92.7% of patients, edema was noted in 5.2% of patients, and mucopurulence in 2% of patients. The majority of patients described their pain as frontal or frontal-maxillary, dull or throbbing, and moderate to severe. Migraine was the most common final diagnosis in 49.1% of patients and the second most common diagnosis was tension-type headache in 17.3%. The remaining patients were diagnosed with 11 additional ICHD diagnoses.</p><p><strong>Conclusions: </strong>Patients referred from a rhinologist to a headache specialist for nonsinogenic craniofacial pain are frequently diagnosed with primary headache disorder, specifically migraine or tension-type headache. Collaboration between specialists may improve diagnostic accuracy and outcomes, although further studies are crucial.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylphenidate-Induced Stuttering in a Patient With Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: A Case Report.","authors":"Irem Yildirim, Ibrahim Adak, Ipek Suzer Gamli, Ozalp Ekinci","doi":"10.1097/WNF.0000000000000640","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000640","url":null,"abstract":"<p><strong>Objective: </strong>Autism spectrum disorder (ASD) is a common neurodevelopmental condition marked by difficulties in social communication and interaction, along with the presence of repetitive behaviors or interests. ASD often co-occurs with attention deficit hyperactivity disorder (ADHD), and this comorbidity should be considered when developing a treatment plan. Methylphenidate (MPH) is a psychostimulant that is commonly used as the first-line treatment for ADHD. Despite its high effectiveness, adverse effects may occur especially in children with co-occurring ASD. Here, we aimed to present a case with ASD and ADHD who developed stuttering with the onset of MPH and discuss the literature.</p><p><strong>Method and results: </strong>A 10.5-year-old boy with ASD was referred to our clinic due to symptoms of inattention, hyperactivity, and impulsivity. He was diagnosed with ADHD and prescribed OROS MPH at 18 mg/day, which was increased to 27 mg/day after 1 month. His ADHD symptoms moderately improved, but he began stuttering 1 week after the dosage increase. After discontinuing the medication, his speech fluency significantly improved. Three months later, OROS MPH was reintroduced at 27 mg/day, and the stuttering resumed. Consequently, MPH was discontinued, and his treatment is now being managed with atomoxetine.</p><p><strong>Conclusions: </strong>Despite that the relationship between MPH and stuttering is not well-documented, it is important to recognize that side effects may arise when initiating treatment or increasing the dosage. Typically, quitting the medication is sufficient to alleviate these side effects. Further studies are needed to better understand the side effects and mechanisms of action associated with MPH.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Oxcarbazepine as Monotherapy for Prevention of Epileptic Seizures in Patients With Supratentorial Brain Tumors: A Prospective Multicentric Study.","authors":"Ibrahim Omerhodžić, Bekir Rovčanin, Almir Džurlić, Mirsad Hodžić, Rasim Skomorac, Hakija Bečulić, Salko Zahirović, Fahrudin Alić, Enra Suljić, Aziz Šukalo, Meliha Mehić, Amna Tanović Avdić, Una Glamočlija","doi":"10.1097/WNF.0000000000000639","DOIUrl":"10.1097/WNF.0000000000000639","url":null,"abstract":"<p><strong>Objectives: </strong>Brain tumor-related epilepsy management poses significant challenge in clinical practice. Healthcare providers must tailor treatment based on each patient's unique circumstances. Different antiepileptic drugs can be used, including oxcarbazepine. Several studies show this drug's efficacy and safety in brain tumor-related epilepsy.</p><p><strong>Methods: </strong>Observational, prospective study, monitoring the efficacy and safety of the drug oxcarbazepine in the prevention of epileptic seizures, included adult patients of both sexes with a supratentorial tumor and a risk of epileptic seizures after neurosurgery.</p><p><strong>Results: </strong>The study included 153 hospitalized patients. The percentages of amplified waves, sharp waves, and spike waves decreased in the second and third compared with the first visit. Significantly lower percentages of sharp waves (P = 0.028) on the second compared with the first measurement and spike waves (P = 0.002) on the third compared with the first measurement were determined. Deterioration from normal to low hemoglobin concentration was observed in 40 (26%) patients at the second visit and 17 (12%) at the third visit, compared with the first visit. However, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration values did not change significantly during the 6 months of follow-up. A transient drop in the number of thrombocytes was observed on the second visit. Adverse reactions to the drug were mild. Therapeutic adherence was low, as measured by the Morisky Medication Adherence Scale (MMAS-4).</p><p><strong>Conclusions: </strong>The drug oxcarbazepine has shown good efficacy and safety in the prevention of epileptic attacks after neurosurgery in patients with supratentorial tumors. Additional education of patients on the importance of taking regular therapy is crucial.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amantadine Reduces Adverse Cardiovascular Outcomes in Patients With Parkinsonism or Parkinson Disease: A Global Propensity Score Matched Analysis.","authors":"Dan Draytsel, Anderson Anuforo, Subaina Khalid, Bharat Rawlley, Kavipriya Kovai Palanivel, Jacob Charlamb, Jonathan Miller, Mark Charlamb","doi":"10.1097/WNF.0000000000000628","DOIUrl":"10.1097/WNF.0000000000000628","url":null,"abstract":"<p><strong>Objective: </strong>N -methyl- d -aspartate (NMDA) receptor antagonism in the central nervous system has been described. More data are needed regarding its clinical impact on the cardiovascular system. In this study, we assess the cardiovascular impact of NMDA receptor antagonism with amantadine on patients with primary or secondary parkinsonism.</p><p><strong>Methods: </strong>To conduct this retrospective cohort analysis, we queried the TriNetX Global database on January 13, 2024 to identify patients 18 years old or older with Parkinsonism between January 2003 and December 2023 and divided them into 2 groups based on amantadine use. We conducted propensity score matched (PSM) analysis for sociodemographics, cardiovascular comorbidities and medications, and antiparkinsonian agents.</p><p><strong>Results: </strong>After PSM, relative risks (RRs) were used to compare outcomes over a 5-year follow-up period. After PSM, both groups had 28,461 patients each. Amantadine use in patients with parkinsonism was associated with a 13% reduction in 3-point major adverse cardiovascular and cerebrovascular events (RR: 0.867, 95% confidence interval [CI]: 0.836-0.900, P < 0.0001), as well as a significantly lower risk of all-cause mortality (RR: 0.877, 95% CI: 0.844-0.912, P < 0.0001), AMI (RR: 0.790, 95% CI: 0.709-0.881, P < 0.0001), and cerebral infarction (RR: 0.868, 95% CI: 0.791-0.952, P = 0.0026). It was also associated with lower rates of heart failure, atrial arrhythmias, bradycardia, atrioventricular blocks, ventricular tachycardia, syncope and collapse, and peripheral edema. Amantadine use was however associated with a higher risk of orthostatic hypotension.</p><p><strong>Conclusions: </strong>NMDA antagonism with amantadine in patients with primary or secondary parkinsonism is associated with a significantly reduced risk of all-cause mortality, AMI, cerebral infarction, heart failure, and arrhythmias.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"67-72"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Age and Severity of Attention Deficit Hyperactivity Disorder (ADHD) Before COVID-19 on the Severity of ADHD During the COVID-19 Lockdowns, as Reported by the Mothers.","authors":"Pavel Golubchik, Abraham Weizman","doi":"10.1097/WNF.0000000000000632","DOIUrl":"10.1097/WNF.0000000000000632","url":null,"abstract":"<p><strong>Objectives: </strong>This cohort study aimed to better understand the relationship between attention deficit hyperactivity disorder (ADHD) severity predating the COVID-19 outbreak, in children with ADHD, and the severity of ADHD symptoms during the COVID-19 lockdowns.</p><p><strong>Methods: </strong>Age and clinical data, including ADHD-Rating Scale scores, of 30 children and adolescents with ADHD, aged 7-18 years, were collected from medical files, for the 6-month period that predated the COVID-19 outbreak. During the COVID-19 lockdowns, the children's ADHD severity was evaluated by the mothers using the Clinical Global Impression-Severity scale (CGI-S). The correlations of CGI-S scores with age and above-mentioned ADHD-Rating Scale scores that were collected before COVID-19 were then assessed.</p><p><strong>Results: </strong>Significant correlation was found between age of participants and CGI-S scores ( P = 0.034). Additionally, participants who continued ADHD pharmacological treatment ( P = 0.02) and used remote clinical treatment ( P = 0.008) demonstrated lower mother reported CGI-S scores.</p><p><strong>Conclusions: </strong>In children with ADHD, younger age, ongoing stimulant-treatment and ongoing remote visits with a caretaker, seem to correlate with lower ADHD-symptom severity during COVID-19 lockdowns.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"86-88"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rising Drug Burden Index Is Related With Malnutrition in Community-Dwelling Older Adults With Dementia.","authors":"Sultan Keskin Demircan, Mehmet Ilkin Naharci","doi":"10.1097/WNF.0000000000000629","DOIUrl":"10.1097/WNF.0000000000000629","url":null,"abstract":"<p><strong>Objectives: </strong>Malnutrition is common in dementia patients and can lead to poor outcomes. Also, these patients are often prescribed medications with sedative and anticholinergic effects for various reasons. Thus, we aimed to explore the relationship between drug burden index (DBI), anticholinergic burden (ACB), and nutrition status in community-dwelling older adults with dementia.</p><p><strong>Method: </strong>A total of 415 outpatients with dementia, evaluated by Mini Nutrition Assessment, and whose drug information is registered are included in study. DBI score was calculated by summing the scores of regularly used anticholinergic and/or sedative drugs taken for at least four weeks prior to admission.</p><p><strong>Results: </strong>The mean age of participants was 77.4 ± 6.3 years, and the majority were female (64.3%). The most prevalent type of dementia (71.6%) was Alzheimer's dementia. The prevalence of malnutrition is 23.6%. Polypharmacy was present in approximately half of the participants (47.5). In total, 57.0% of the participants were using anticholinergic drugs, and 77% of the participants had drug exposure. In the fully adjusted multivariate models, an increase in DBI score raised the risk of \"malnutrition\" by 2.12 times (OR, 2.12; 95% CI, 1.15-4.01; P = 0.02), whereas no relationship was determined between ACB score and \"malnutrition\" (OR, 1.21; 95% CI, 0.98-1.49; P = 0.07).</p><p><strong>Conclusions: </strong>Older adults with dementia are frequently exposed to drugs with sedative and anticholinergic properties. Considering the relationship between DBI and malnutrition, these drugs and doses should be optimized to prevent malnutrition and its adverse outcomes in this vulnerable population.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"73-78"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Pain Control in Headaches Associated With Subarachnoid Hemorrhage.","authors":"Lindsey F East, Leslie A Hamilton, Thomas Christianson, Terrance Nowell, Mary Kathleen Ryan, Anthony Shaun Rowe","doi":"10.1097/WNF.0000000000000631","DOIUrl":"10.1097/WNF.0000000000000631","url":null,"abstract":"<p><strong>Objectives: </strong>Intractable headaches are a common occurrence in patients experiencing an aneurysmal subarachnoid hemorrhage (aSAH). Utilization of multimodal pain management regimens has become the standard of care for the treatment of acute and chronic pain. The primary objective of this study was to evaluate the use of a new multimodal pain regimen for headache in patients who have experienced aSAH.</p><p><strong>Methods: </strong>This was an Institutional Review Board approved study evaluating the use of a multimodal pain regimen for treatment of headache pain in 104 patients who experienced aSAH in a neuro intensive care unit. Patients diagnosed with aSAH from January 2017 to December 2019, which was prior to the implementation of the multimodal pain regimen, were compared to aSAH patients from March 2020 through 2022, who were treated with the multimodal pain regimen. The primary endpoint was morphine milligram equivalent usage during the first 5 days of admission before and after the implementation of the multimodal pain regimen. The secondary endpoints were pain scores during the first 5 days of admission.</p><p><strong>Results: </strong>As compared to those who did not receive the aSAH headache pathway (n = 39, premultimodal regimen), those who did receive the pathway (n = 65, multimodal regimen) received significantly more morphine milligram equivalents over the first 5 days of admission (30.0 [0, 97.5] vs 82.5 [15, 135]); P = 0.0053. There was no difference in the median average pain score.</p><p><strong>Conclusions: </strong>The MM pain pathway did not reduce the total morphine equivalents utilized for the treatment of aSAH-associated headache.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"89-92"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy.","authors":"Özdem Ertürk Çetin, Pınar Algedik, Gülcan Akyüz, Reyhan Sürmeli, Ümit Zanapalıoğlu, Gülce Alev Saltak, Şirin Güven","doi":"10.1097/WNF.0000000000000600","DOIUrl":"10.1097/WNF.0000000000000600","url":null,"abstract":"<p><strong>Objectives: </strong>The relationship of older antiseizure drugs with congenital malformations has been known for many years. Studies are mostly limited to major malformations and few studies have investigated minor malformations. In recent years, the long-term cognitive and behavioral effects of these drugs have also come to the fore. The aim of our study was to evaluate the incidence of major and minor congenital malformations and neurodevelopmental outcomes in children prenatally exposed to levetiracetam (LEV), lamotrigine (LTG), and carbamazepine (CBZ) monotherapy.</p><p><strong>Methods: </strong>This was a prospective observational study conducted in two university hospital epilepsy centers. It included 32 pregnant women who were continuously treated with LEV, LTG, or CBZ from conception throughout pregnancy. Children were followed up from birth until 18 months. Neurodevelopmental outcomes were evaluated with the Ages and Stages Questionnaire and Denver Developmental Screening Test.</p><p><strong>Results: </strong>Eighteen of the patients were on LEV, 10 were on LTG, and 4 were on CBZ. Diaphragmatic hernia was detected in a child. At least one minor anomaly was observed in 58.1% of the patients. More than 80% of children were normal in the Ages and Stages Questionnaire.</p><p><strong>Conclusions: </strong>The risk of major congenital malformations is lower with newer antiseizure drugs. We found a high incidence of minor ones. However, because the population prevalence of minor malformations is also variable, more studies are needed to confirm the results. Neurodevelopmental outcomes were favorable with LTG and LEV and slightly unfavorable with CBZ. Longer-term follow-up with large groups of children is required to reach more reliable results.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"61-66"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-Year Retention Rate and Clinical Usefulness of Eslicarbazepine Acetate in Epilepsy Patients.","authors":"Hyun Kyung Kim, Dong Won Kwack, Dong Wook Kim","doi":"10.1097/WNF.0000000000000633","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000633","url":null,"abstract":"<p><strong>Objective: </strong>Eslicarbazepine acetate (ESL) is a third-generation antiseizure medication (ASM) approved for the treatment of focal seizures. Because of the delayed approval of ESL in Asian countries, there is limited information on the clinical usefulness of ESL in the Asian population. We performed a retrospective analysis of retention rate and seizure outcomes for ESL treatment in Korean epilepsy patients.</p><p><strong>Methods: </strong>A 2-year retrospective observational study was conducted, in which 160 epilepsy patients (82 males; age range, 17-81 years) were treated with ESL. The starting dose of ESL was 400 mg/d, and optimal dose adjustments were made based on individual clinical responses. We analyzed efficacy and tolerability during the 2-year follow-up period.</p><p><strong>Results: </strong>This study found that the overall retention rate was 81.5% at 1 year and 76.1% at 2 years. The retention rate at 2 years was 86.5% in the monotherapy group and 69.8% in the adjunctive therapy group. Adverse events, mostly dizziness/somnolence and skin eruption, were reported in 38 (23.8%) of patients, leading to discontinuation of ESL in 24 patients. Laboratory hyponatremia was noted in 2 patients, but neither of them experienced symptomatic hyponatremia. Switching from other dibenzazepine ASMs, carbamazepine and oxcarbazepine, was performed in 31 patients (19.4%), and most patients (26 of 31 patients, 83.9%) continued to take ESL until their last follow-up.</p><p><strong>Conclusions: </strong>Our study demonstrates that treatment with ESL results in favorable retention rates and tolerability among Korean epilepsy patients, which is consistent with data from Western countries. Additionally, our findings suggest that ESL-induced hyponatremia is infrequent and largely asymptomatic when used cautiously and switching from other dibenzazepine ASMs may be a useful option for selected patients.</p>","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"48 3","pages":"93-96"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}